Immune-modulating effects of alpha-1 antitrypsin

Por Ehlers, Mario R.
Publicado no Biol Chem (2014)

Immune Interventions to Preserve Beta Cell Function in Type 1 Diabetes

Por Ehlers, Mario R.
Publicado no J Investig Med (2016)

Strategies for clinical trials in type 1 diabetes

Por Ehlers, Mario R.
Publicado no J Autoimmun (2016)

Immune-Directed Therapy for Type 1 Diabetes at the Clinical Level: The Immune Tolerance Network (ITN) Experience

Por Ehlers, Mario R., Nepom, Gerald T.
Publicado em 2012

Targeted Immune Interventions for Type 1 Diabetes: Not as Easy as it Looks!

Por Rigby, Mark R, Ehlers, Mario R
Publicado em 2014

Restoring the balance: immunotherapeutic combinations for autoimmune disease

Por Smilek, Dawn E., Ehlers, Mario R., Nepom, Gerald T.
Publicado em 2014

Correlation Between Hypoglycemia, Glycemic Variability and C-Peptide Preservation After Alefacept Therapy in Patients with Type 1 Diabetes: Analysis of Data from the ITN T1DAL Tria...

Por Pinckney, Ashley, Rigby, Mark R., Keyes-Elstein, Lynette, Soppe, Carol L., Nepom, Gerald T., Ehlers, Mario R.
Publicado no Clin Ther (2016)

The N domain of somatic angiotensin-converting enzyme negatively regulates ectodomain shedding and catalytic activity

Por Woodman, Zenda L., Schwager, Sylva L. U., Redelinghuys, Pierre, Carmona, Adriana K., Ehlers, Mario R. W., Sturrock, Edward D.
Publicado em 2005

Deglycosylation, processing and crystallization of human testis angiotensin-converting enzyme.

Por Gordon, Kerry, Redelinghuys, Pierre, Schwager, Sylva L U, Ehlers, Mario R W, Papageorgiou, Anastassios C, Natesh, Ramanathan, Acharya, K Ravi, Sturrock, Edward D
Publicado em 2003

Two- and Four-Hour Tests Differ in Capture of C-Peptide Responses to a Mixed Meal in Type 1 Diabetes

Por Boyle, Karen D., Keyes-Elstein, Lynette, Ehlers, Mario R., McNamara, James, Rigby, Mark R., Gitelman, Stephen E., Weiner, Lia J., Much, Kristen L., Herold, Kevan C.
Publicado no Diabetes Care (2016)

Changes in T cell subsets identify responders to FcR non-binding anti-CD3 mAb (teplizumab) in patients with Type 1 diabetes

Por Tooley, James E, Vudattu, Nalini, Choi, Jinmyung, Cotsapas, Chris, Devine, Lesley, Raddassi, Khadir, Ehlers, Mario R, McNamara, James G, Harris, Kristina M, Kanaparthi, Sai, Phippard, Deborah, Herold, Kevan C
Publicado no Eur J Immunol (2015)

Glycan microarray reveal induced IgGs repertoire shift against a dietary carbohydrate in response to rabbit anti-human thymocyte therapy

Por Amon, Ron, Ben-Arye, Shani Leviatan, Engler, Limor, Yu, Hai, Lim, Noha, Berre, Ludmilla Le, Harris, Kristina M., Ehlers, Mario R., Gitelman, Stephen E., Chen, Xi, Soulillou, Jean-Paul, Padler-Karavani, Vered
Publicado no Oncotarget (2017)

Teplizumab (Anti-CD3 mAb) Treatment Preserves C-Peptide Responses in Patients With New-Onset Type 1 Diabetes in a Randomized Controlled Trial: Metabolic and Immunologic Features at...

Por Herold, Kevan C., Gitelman, Stephen E., Ehlers, Mario R., Gottlieb, Peter A., Greenbaum, Carla J., Hagopian, William, Boyle, Karen D., Keyes-Elstein, Lynette, Aggarwal, Sudeepta, Phippard, Deborah, Sayre, Peter H., McNamara, James, Bluestone, Jeffrey A.
Publicado em 2013

Antithymocyte globulin therapy for patients with recent-onset type 1 diabetes: 2 year results of a randomised trial

Por Gitelman, Stephen E., Gottlieb, Peter A., Felner, Eric I., Willi, Steven M., Fisher, Lynda K., Moran, Antoinette, Gottschalk, Michael, Moore, Wayne V., Pinckney, Ashley, Keyes-Elstein, Lynette, Harris, Kristina M., Kanaparthi, Sai, Phippard, Deborah, Ding, Linna, Bluestone, Jeffrey A., Ehlers, Mario R.
Publicado no Diabetologia (2016)

Rapamycin/IL-2 Combination Therapy in Patients With Type 1 Diabetes Augments Tregs yet Transiently Impairs β-Cell Function

Por Long, S. Alice, Rieck, Mary, Sanda, Srinath, Bollyky, Jennifer B., Samuels, Peter L., Goland, Robin, Ahmann, Andrew, Rabinovitch, Alex, Aggarwal, Sudeepta, Phippard, Deborah, Turka, Laurence A., Ehlers, Mario R., Bianchine, Peter J., Boyle, Karen D., Adah, Steven A., Bluestone, Jeffrey A., Buckner, Jane H., Greenbaum, Carla J.
Publicado em 2012

Targeting effector memory T cells with alefacept in new onset type 1 diabetes: 12 month results from the T1DAL study

Por Rigby, Mark R, DiMeglio, Linda A, Rendell, Marc S, Felner, Eric I, Dostou, Jean M, Gitelman, Stephen E, Patel, Chetanbabu M, Griffin, Kurt J, Tsalikian, Eva, Gottlieb, Peter A, Greenbaum, Carla J, Sherry, Nicole A, Moore, Wayne V, Monzavi, Roshanak, Willi, Steven M, Raskin, Philip, Moran, Antoinette, Russell, William E, Pinckney, Ashley, Keyes-Elstein, Lynette, Howell, Michael, Aggarwal, Sudeepta, Lim, Noha, Phippard, Deborah, Nepom, Gerald T, McNamara, James, Ehlers, Mario R
Publicado em 2013

Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients

Por Rigby, Mark R., Harris, Kristina M., Pinckney, Ashley, DiMeglio, Linda A., Rendell, Marc S., Felner, Eric I., Dostou, Jean M., Gitelman, Stephen E., Griffin, Kurt J., Tsalikian, Eva, Gottlieb, Peter A., Greenbaum, Carla J., Sherry, Nicole A., Moore, Wayne V., Monzavi, Roshanak, Willi, Steven M., Raskin, Philip, Keyes-Elstein, Lynette, Long, S. Alice, Kanaparthi, Sai, Lim, Noha, Phippard, Deborah, Soppe, Carol L., Fitzgibbon, Margret L., McNamara, James, Nepom, Gerald T., Ehlers, Mario R.
Publicado no J Clin Invest (2015)